Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Evaluation of Immune Cell Therapy in Esophageal Cancer Resistant to Immunochemotherapy.

Anticancer research·2025
Same author

[A Case of Remarkable Immune-Cell Therapy Efficacy in a Patient with Renal Pelvic Cancer Refractory to Immune Checkpoint Inhibitors and Chemotherapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2025
Same author

Personalized Dendritic-cell-based Vaccines Targeting Cancer Neoantigens.

Anticancer research·2024
Same author

A pilot study on the safety and efficacy of neoadjuvant chemo‑adoptive immunotherapy for locally advanced rectal cancer.

Oncology letters·2024
Same author

Effects of adoptive T-cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma.

International journal of cancer·2023
Same author

Safety evaluation of immune-cell therapy for malignant tumor in the Cancer Immune-cell Therapy Evaluation Group (CITEG).

Cytotherapy·2023

Related Experiment Video

Updated: May 5, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

10.9K

Zoledronate-pulsed dendritic cell-based anticancer vaccines.

Takashi Kamigaki1, Masashi Takahara, Ryuji Maekawa

  • 1Seta Clinic; Tokyo, Japan.

Oncoimmunology
|December 10, 2013
PubMed
Summary

Zoledronate added to dendritic cells (DCs) enhances T-cell responses against tumor antigens. This immunotherapy approach shows promise for cancer treatment, as seen in clinical trials.

Keywords:
Wilms’ tumor 1dendritic cellelectroporationintratumoral injectiontumor-associated antigen-derived peptidezoledronate

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

2.2K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

17.7K

Related Experiment Videos

Last Updated: May 5, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

10.9K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

2.2K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

17.7K

Area of Science:

  • Immunology
  • Oncology
  • Vaccine Development

Background:

  • Dendritic cells (DCs) are crucial for initiating immune responses.
  • Tumor-associated antigens (TAAs) are targets for cancer immunotherapy.
  • Zoledronate is a bisphosphonate with immunomodulatory properties.

Purpose of the Study:

  • To investigate the effect of zoledronate on TAA-loaded DC-based vaccines.
  • To evaluate the induction of specific T-cell responses by this combination therapy.
  • To explore the potential therapeutic implications in cancer treatment.

Main Methods:

  • Loading DCs with TAAs.
  • Pulsing DCs with zoledronate.
  • Assessing Vγ9 γδ T cell activation and interferon-γ secretion.
  • Measuring TAA-specific CD8+ T-cell responses.

Main Results:

  • Zoledronate addition significantly promoted the activation of interferon-γ-secreting Vγ9 γδ T cells.
  • This activation led to the elicitation of TAA-specific CD8+ T-cell responses.
  • Zoledronate-pulsed DC vaccines demonstrated therapeutic effects in clinical trials.

Conclusions:

  • Zoledronate enhances the immunogenicity of TAA-loaded DC vaccines.
  • The combination therapy effectively stimulates anti-tumor T-cell immunity.
  • This approach holds potential for improving cancer immunotherapy outcomes.